- Home
- TNYA vs ENLV Comparison
TNYA vs ENLV Comparison
Compare TNYA & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNYA | ENLV |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.5M | 149.0M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TNYA | ENLV |
|---|---|---|
| Price | $0.80 | $4.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $5.33 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 2.7M | 377.1K |
| Earning Date | 05-07-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.96 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $0.43 |
| 52 Week High | $2.35 | $7.64 |
Technical Indicators
Market Signals| Indicator | TNYA | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 50.07 | 65.46 |
| Support Level | $0.65 | $0.79 |
| Resistance Level | $0.80 | $7.64 |
| Average True Range (ATR) | 0.07 | 0.45 |
| MACD | 0.00 | 0.36 |
| Stochastic Oscillator | 39.32 | 59.51 |
Price Performance
Historical ComparisonAbout TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.